A detailed history of Dafna Capital Management LLC transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Dafna Capital Management LLC holds 231,748 shares of MORF stock, worth $7.9 Million. This represents 1.96% of its overall portfolio holdings.

Number of Shares
231,748
Previous 231,748 -0.0%
Holding current value
$7.9 Million
Previous $6.69 Million 21.89%
% of portfolio
1.96%
Previous 1.69%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$21.33 - $59.42 $533,250 - $1.49 Million
25,000 Added 12.09%
231,748 $5.31 Million
Q2 2023

Aug 14, 2023

BUY
$34.33 - $62.11 $936,556 - $1.69 Million
27,281 Added 15.2%
206,748 $11.9 Million
Q1 2023

May 15, 2023

SELL
$26.01 - $48.69 $416,160 - $779,040
-16,000 Reduced 8.19%
179,467 $6.76 Million
Q2 2022

Aug 15, 2022

BUY
$19.74 - $43.01 $276,360 - $602,140
14,000 Added 7.71%
195,467 $4.24 Million
Q1 2021

May 17, 2021

BUY
$29.77 - $84.85 $3.57 Million - $10.2 Million
120,000 Added 195.23%
181,467 $11.5 Million
Q4 2020

Feb 16, 2021

BUY
$25.66 - $34.55 $1.58 Million - $2.12 Million
61,467 New
61,467 $2.06 Million
Q3 2020

Nov 16, 2020

SELL
$22.51 - $30.11 $675,300 - $903,300
-30,000 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$12.65 - $29.57 $88,550 - $206,990
-7,000 Reduced 18.92%
30,000 $812,000
Q4 2019

Feb 14, 2020

BUY
$13.02 - $19.5 $481,740 - $721,500
37,000 New
37,000 $635,000
Q3 2019

Nov 14, 2019

SELL
$17.46 - $29.05 $1.05 Million - $1.74 Million
-60,000 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$18.0 - $19.82 $1.08 Million - $1.19 Million
60,000 New
60,000 $1.19 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $1.31B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Dafna Capital Management LLC Portfolio

Follow Dafna Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.